---
document_datetime: 2025-07-03 11:24:49
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-pfizer-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: pregabalin-pfizer-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.4207114
conversion_datetime: 2025-12-27 14:44:08.91301
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pregabalin Pfizer

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| WS/2708              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study A0081096 listed as a category 3 study in the RMP. This is a | 05/09/2024                          | n/a                                         |                                  | Submission of the final report from study A0081096. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | prospective randomized 12-week controlled study of visual field change in subjects with partial seizures receiving pregabalin or placebo. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |      |                                                                                                                                                                                                                                        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0058    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/08/2024 | 03/02/2025 | PL   |                                                                                                                                                                                                                                        |
| WS/2520/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Grouped application comprising two type II as follows: C.I.4 - Update of sections 4.4 of the SmPC in order to add information on potential abuse in recreational drug users based on final results from study A0081365 'A Phase 4 Randomized Double-Blind Double-Dummy Placebo- and Active-Controlled Single-Dose Six-way Crossover Study Evaluating the Abuse Potential of Lyrica Taken Orally with Oxycodone HCl in Healthy Non-Drug Dependent Recreational Opioid Users'. A.6 - To change the ATC Code from N03AX16 to N02BF02. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 16/05/2024 | 03/02/2025 | SmPC | Update of sections 4.4 of the SmPC in order to add information on potential abuse in recreational drug users based on final results from study A0081365. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                    | data A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                 |                                                                                                                                           |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1734            | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                                                                                                                                                                                                   | 05/04/2024 | n/a        |                 |                                                                                                                                           |
| IG/1690/G          | This was an application for a group of variations. B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 11/01/2024 | 03/02/2025 | Annex II and PL |                                                                                                                                           |
| PSUSA/2511/ 202301 | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                                                                  | 12/10/2023 | 07/12/2023 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2511/202301. |
| N/0054             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                          | 15/09/2023 | 07/12/2023 | PL              |                                                                                                                                           |
| IG/1622            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                | 31/07/2023 | n/a        |                 |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| N/0050   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                            | 14/03/2023   | 07/12/2023   | PL          |                                                                                                                                                                                                          |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0049   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                            | 29/07/2022   | 26/09/2022   | PL          |                                                                                                                                                                                                          |
| WS/2293  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                | 21/07/2022   | 26/09/2022   | SmPC and PL | To update sections 4.4 and 4.8 of the SmPC and sections 2, 3 and 4 of the PL, to implement the wording related to the cases of abuse and dependence in patients without a history of substance disorder. |
| WS/2261  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of SmPC sections 4.4 and 4.8 with a warning regarding severe cutaneous adverse reactions (SJS and TEN). C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 10/06/2022   | 26/09/2022   | SmPC and PL |                                                                                                                                                                                                          |
| WS/2168  | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3.z - Change(s) in the SPC, Labelling or PL                                                                                                                                                               | 22/04/2022   | 26/09/2022   | SmPC and PL |                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                    | intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0046             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 07/03/2022 | 26/09/2022 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| N/0045             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/12/2021 | 26/09/2022 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| PSUSA/2511/ 202101 | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/09/2021 | 15/11/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2511/202101.                                                                                                                                                                                                                                                                                                                                                                                       |
| WS/1919            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of an updated RMP (version 13.2) to include results from recently completed PASS studies, namely: 1) study A0081359: a population- based cohort study of pregabalin to characterize pregnancy outcomes; 2) study A0081106: a 12- month open-label study to evaluate the safety and tolerability of pregabalin as adjunctive therapy in paediatric subjects 1 month to 16 years of age with partial onset seizures and paediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures; 3) study A0081042: a double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of pregabalin as adjunctive therapy in children | 28/10/2021 | 26/09/2022 | SmPC and PL | The results from the pregnancy outcomes study provided additional information concerning the risks of pregabalin treatment during pregnancy; supporting that pregabalin should not be used during pregnancy unless clearly necessary and women of childbearing potential have to use effective contraception based on the new data on major congenital malformations. In addition, the data support that pregabalin may cross the human placenta. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| 1 month through <4 years seizures; 4) study A0081105: blind, placebo-controlled, trial of pregabalin as adjunctive and adult subjects with primary clonic seizures. In addition, A0081096: a prospective controlled study of visual with partial seizures receiving has been updated as well randomised, double-blind, and active-controlled, single-dose, study to evaluate the potential pregabalin. However, further RMP should be updated opportunity. In the light of the results outcomes study, section updated concerning the during pregnancy, indicating childbearing potential have contraception, pregabalin placenta and the description malformations (MCM). In updated to highlight that used during pregnancy unless women of childbearing potential contraception based on the C.I.11.b - Introduction of, obligations and conditions   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | which require to be further substantiated new additional data to be submitted by the MAH significant assessment is required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             | change(s) by where   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------|
| N/0044  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 18/10/2021 | 26/09/2022 | PL          |                      |
| N/0042  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/08/2021 | 15/11/2021 | PL          |                      |
| WS/2015 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. To update Section 5.1 of the SmPC following completion of a paediatric study (A0081105) in line with the outcome of the Article 46 (EMEA/H/C/003880/P46/006.1 and EMEA/H/C/003880/P46/006) and Post-authorisation Measure (PAM) procedure (EMEA/H/C/000546/P46/053.1 and EMEA/H/C/003880/P46/006.1). In addition the MAH brought that annexes in line with QRD version 10.1 and a reference to the reporting of side effects that had been duplicated was removed. C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 25/03/2021 | 15/11/2021 | SmPC and PL |                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/2511/ 202001   | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 17/09/2020   | 18/11/2020   | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2511/202001.                                                                                                                                                                                                                                                                                                                                     |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0039               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/10/2020   | 15/11/2021   | Labelling              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| WS/1798              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update Section 4.8 and Section 5.1 SmPC to reflect data from study A0081106 'A 12-Month Open-Label Study to Evaluate the Safety and Tolerability of Pregabalin as Adjunctive Therapy in Pediatric Subjects 1 Month to 16 Years of Age With Partial Onset Seizures and Pediatric and Adult Subjects 5 to 65 Years of Age With Primary Generalized Tonic- Clonic Seizures'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 03/09/2020   | 18/11/2020   | SmPC, Labelling and PL | Section 4.8 and Section 5.1 of the SmPC were updated to reflect safety results from study A0081106 'A 12-Month Open-Label Study to Evaluate the Safety and Tolerability of Pregabalin as Adjunctive Therapy in Pediatric Subjects 1 Month to 16 Years of Age With Partial Onset Seizures and Pediatric and Adult Subjects 5 to 65 Years of Age With Primary Generalized Tonic-Clonic Seizures'. For more information, please refer to the Summary of Product Characteristics. |
| T/0035               | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 03/04/2020   | 02/06/2020   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IG/1245/G            | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved                                                                                                                                                                                                                                                                                                                                                                                                                                   | 29/05/2020   | n/a          |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         | manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0034  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/03/2020 | 02/06/2020 | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| WS/1605 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Addition of a warning in section 4.4. regarding an increased risk for opioid related death in patients who took concomitant opioids. A statement on the observation of a trend for a greater risk at higher doses was also included. Section 4.5 has been updated to reflect the findings of the case-control study regarding concomitant use of pregabalin and                                                                                                                                                                                          | 14/11/2019 | 09/03/2020 | SmPC and PL | Based on published literature and a cumulative review of cases in the MAH's safety database, there is a strong signal for an increased risk of opioid-related death in patients concomitantly receiving opioids and pregabalin compared to treatment with opioids alone. Consequently, a new warning regarding an increased risk for opioid related death in patients who took concomitant opioids has been added in SmPC section 4.4. Moreover, Section 4.5 has been updated to reflect the findings of the case-control study regarding concomitant use of pregabalin and opioids. |

<div style=\"page-break-after: always\"></div>

|                    | opioids. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                 |            |            |                        |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| N/0032             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                           | 13/11/2019 | 09/03/2020 | PL                     |                                   |
| PSUSA/2511/ 201901 | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                   | 05/09/2019 | n/a        |                        | PRAC Recommendation - maintenance |
| IG/1123            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient               | 30/08/2019 | n/a        |                        |                                   |
| N/0030             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                           | 21/05/2019 | 09/03/2020 | PL                     |                                   |
| IG/1103            | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                         | 17/05/2019 | 09/03/2020 | SmPC, Labelling and PL |                                   |
| WS/1495            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 28/02/2019 | 09/03/2020 | SmPC                   |                                   |

<div style=\"page-break-after: always\"></div>

|                    | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                                                                                                                                                                                                                                                                                |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0025             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/10/2018 | 12/12/2018 | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Pregabalin Pfizer in the approved indication remains unchanged and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| WS/1364            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Introduction of an updated RMP version 12.3 in order to include the changes proposed by EMEA/H/C/PSUSA/00002511/201701, updating the safety concerns and risk minimisation measures. The pharmacovigilance plan has also been updated. The protocol for non-interventional non-imposed PASS (A0081359) titled 'A population-based cohort study of Pregabalin to characterize pregnancy outcomes' has been approved. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 29/11/2018 | n/a        |                                                                                                                                                                                                                                                                                |
| PSUSA/2511/ 201801 | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/09/2018 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| T/0024    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/07/2018   | 30/07/2018   | SmPC, Labelling and PL   |                                                                                                                                                                                                                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0938/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) | 13/07/2018   | n/a          |                          |                                                                                                                                                                                                                             |
| WS/1137   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/11/2017   | 07/03/2018   | SmPC                     | In the 12 week placebo controlled study, paediatric patients were assigned to pregabalin 2.5 mg/kg/day (maximum, 150 mg/day), pregabalin 10 mg/kg/day (maximum, 600 mg/day), or placebo. The percentage of subjects with at |

<div style=\"page-break-after: always\"></div>

|                    | Update of sections 4.8 and 5.1 of the SmPC in order to reflect final results from paediatric study A0081041: 'A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Pregabalin as Adjunctive Therapy in Children 4-16 Years of Age with Partial Onset Seizures'. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        | least a 50% reduction in partial onset seizures as compared to baseline was 40.6% of subjects treated with pregabalin 10 mg/kg/day (p=0.0068 versus placebo), 29.1% of subjects treated with pregabalin 2.5 mg/kg/day (p=0.2600 versus placebo) and 22.6% of those receiving placebo. The most common adverse events observed in the 12 week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis.   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/1213            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                | 14/09/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/2511/ 201701 | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                                           | 01/09/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| WS/1200            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                       | 06/07/2017 | 07/03/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| WS/1121            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                      | 16/03/2017 | 07/03/2018 | SmPC, Labelling and    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                    | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                              |            |            | PL                               |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2511/ 201601 | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                         | 15/09/2016 | 11/11/2016 | SmPC, Annex II, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2511/201601. |
| N/0014             | Update of the package leaflet with revised contact details of the local representative for Germany. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                             | 17/06/2016 | 11/11/2016 | PL                               |                                                                                                                                           |
| IG/0683            | B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS                                                                                                                                                                                                                                   | 13/05/2016 | n/a        |                                  |                                                                                                                                           |
| IA/0011/G          | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting | 04/04/2016 | n/a        |                                  |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)   |            |            |           | new or an already   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|---------------------|
| N/0010  | Update of the Annex IIIA for the bottle label for Pregabalin Pfizer 75 mg hard capsules (pack of 200) presentation (EU/1/14/916/018) to align with the currently approved text for the brand product, Lyrica. Minor change in labelling or package leaflet not with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                            | 16/02/2016 | 11/11/2016 | Labelling | connected           |
| IA/0008 | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/10/2015 | n/a        |           |                     |
| IB/0009 | B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/10/2015 | n/a        |           |                     |

<div style=\"page-break-after: always\"></div>

| PSUSA/2511/ 201501   | Periodic Safety Update EU Single assessment - pregabalin                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/09/2015   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                         |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0007            | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                                                                    | 31/07/2015   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                           |
| N/0005               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                             | 24/06/2015   | 11/11/2016 | PL                               |                                                                                                                                                                                                                                                                                                                                           |
| WS/0690              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information as requested after assessment of studies A0081074 & A0081075 submitted as post authorisation measure P46 045. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/03/2015   | 08/07/2015 | SmPC                             | Paediatric information has been added to the SmPC after final assessment of data from two clinical studies assessed during a P46 procedure.                                                                                                                                                                                               |
| WS/0628              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.6 (Fertility, pregnancy, and lactation) and 5.2 (Pharmacokinetic properties) of the SmPC to reflect new data available for lactation,                                                                                                                                                                     | 18/12/2014   | 08/07/2015 | SmPC, Annex II, Labelling and PL | This variation updated sections 4.6 (Fertility, pregnancy, and lactation) and 5.2 (Pharmacokinetic properties) of the SmPC to reflect new data available for lactation, based on the results of a recently completed study, A0081181: A multiple dose pharmacokinetic open label study of pregabalin (LYRICA) in healthy lactating women. |

<div style=\"page-break-after: always\"></div>

|         | based on the results of a recently completed study, A0081181: A multiple dose pharmacokinetic open label study of pregabalin (LYRICA) in healthy lactating women. Package leaflet is updated accordingly. Furthermore editorial changes have been introduced throughout the PI. In addition, the MAH took the opportunity to align the product information with the latest QRD template version 9.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| N/0003  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/09/2014 | 08/07/2015 | PL          |
| IB/0001 | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                           | 24/07/2014 | 08/07/2015 | SmPC and PL |